Creo Medical Group PLC Directorate Change (0488S)

TIDMCREO

RNS Number : 0488S

Creo Medical Group PLC

06 July 2020

Creo Medical Group plc

("Creo" or the "Company")

Directorate Change, Appointment of Chief Commercial Officer to the Board

&

Further strengthening of Senior Management team

Creo Medical Group plc (AIM: CREO), the medical device company focused on the emerging field of surgical endoscopy, announces the following change to the Board and strengthening of the Senior Management team.

Appointment of David Woods as Executive Director (previously Non-Exec)

David Woods, Non-Executive Director, has been appointed as Chief Commercial Officer ('CCO'), with effect from 1 August 2020. David has extensive experience in the med-tech sector and joins the Company in his new full-time executive role based in the USA, having previously been the President and CEO of PENTAX Americas and M&A Director of HOYA Group PENTAX Medical.

David's experience in the Medical Device Market encompasses Gastroenterology, General and Orthopaedic Surgery, Pulmonology and Ear Nose and Throat. Alongside this, David's significant operating experience, market understanding, and proven track record of achievement will benefit the Creo team at a crucial time when the Company is moving from early clinical adoption to global commercialisation expansion. As CCO, David will provide leadership and strategic direction for Creo's Group Commercial divisions overseeing all strategic global commercial activities, which are key to Creo's growth.

For further details on David's experience see here: https://investors.creomedical.com/about-us/board-of-directors

Further Senior Management Appointments

As the Company prepares to accelerate and progress commercially, a President of Sales, Service and Commercial Operations has also been appointed in both the USA and the Asia-Pacific regions to provide a substantial presence, gain market share and revenue within these regions, and give healthcare professionals access to much needed advanced medical technologies and instruments. These appointments, along with other recent appointments, bring with them experience from companies such as Medtronic, Covidien, BARRX, J&J, Pentax, Philips Healthcare, US Endoscopy, and BTG Group.

Creo has also made further senior appointments for US Sales, Service and Commercial operations, Wider EMEA Sales, Global Marketing and Product Management, including marketing communications, Clinical professionals, and Professional Education. The Company is looking to grow the US based team for market and sales development as well as increase the UK based team for business management coverage throughout the UK and EU, and for the key delivery of sales and service operations in all regions. The future growth of the Clinical programme will also provide further recruitment opportunities to expand the clinical team and ensure that clinicians on a global scale are trained in the use of Creo's full suite of devices.

David Woods commented: "I am very fortunate to have worked with a company as great as PENTAX Medical for more than two decades and to have worked with such terrific people. It is certainly an experience where I have learned so much. Making the decision to leave was incredibly difficult, but I am enormously excited by the opportunity that Creo presents as we see increased commercial momentum from Creo's first products and the commercial launch of a wider suite of medical devices that will radically change the way endoscopists and surgeons treat patients worldwide."

Craig Gulliford, CEO of Creo, commented: "Dave has been working with Creo since 2015 and we are delighted that he will be joining us full-time as Chief Commercial Officer, during a key phase in the Company's development as we look to commercialise our wider range advanced energy products. Dave brings with him a wealth of experience in the med-tech sector having been a key driver of the PENTAX Medical Americas team for more than 20 years. Dave has been a great support as a Non-Executive and his decision to join us full-time speak volumes for the commercial opportunity we have before us across multiple applications for our technology. Despite the COVID-19 climate, over the last six months we have been able to attract some terrific commercial talent in addition to Dave joining full time. These senior management additions are fundamental as we expand our commercialisation and come at an exciting time as we launch a range of innovative devices to improve patient outcomes globally."

Enquires:

 
 Creo Medical Group plc                                                www.creomedical.com 
 Richard Rees (CFO)                                                    [phone] 
 
 Cenkos Securities plc                                                 [phone] 
 Stephen Keys / Cameron MacRitchie 
  (NOMAD) 
 Michael Johnson / Russell Kerr (Sales) 
 
 Walbrook PR Ltd                           Tel: [phone] or [e-mail] 
 Paul McManus / Lianne Cawthorne                    Mob: [phone] 
                                                                                   909 238 
 

About Creo Medical

Creo Medical, founded in 2003, is a medical device company focused on the development and commercialisation of minimally invasive surgical devices, by bringing advanced energy to endoscopy. The Company's mission is to improve patient outcomes by applying microwave and RF energy to surgical endoscopy. Creo has developed CROMA, an electrosurgical Advanced Energy Platform that combines bipolar radiofrequency for precise localised cutting and microwave for controlled coagulation. This technology provides clinicians with flexible, accurate and controlled surgical solutions.

The Company's strategy is to bring its CROMA Advanced Energy Platform powered by unique full spectrum adaptive technology to market enabling a suite of medical devices which the Company has designed, initially for the emerging field of GI therapeutic endoscopy, an area with high unmet needs. The CROMA Advanced Energy platform will be developed further for bronchoscopy and laparoscopy procedures. The Company believes its technology can impact the landscape of surgery and endoscopy by providing a safer, less-invasive and more cost-efficient option of treatment.

For more information about Creo Medical please see our website, www.creomedical.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

END

BOABLGDRIUGDGGX

(END) Dow Jones Newswires

July 06, 2020 02:00 ET (06:00 GMT)